Skip to Main Content

Paper Details

Cetuximab in Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Ovarian Cancer Without KRAS, NRAS, or BRAF Mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
Target Oncol
18
2020
Author NameAffiliation
Elizabeth Garrett-MayerAmerican Society of Clinical Oncology
  • 1 - 1

Datasets

Release 1.2